PURPOSE: A single institute trial of combination chemotherapy, with @entity1311 and @entity900 , in @entity1 with metastatic @entity0 , having failed previous combination chemotherapy, was performed. MATERIALS AND METHODS: @entity1 were only eligible for this study if there disease had progressed, following treatment with previous chemotherapy, in either an adjuvant or a metastatic setting. @entity1311 175 mg/m2 was administered as a 3-hour continuous infusion on day 1, and @entity900 80 mg/m2 was administered for 2 hours on day 2, with adequate hydration. This was repeated every 3 weeks, and continued until one of the following events occurred: disease progression, unacceptable adverse effect or treatment refusal by the @entity1 . Intercurrent palliative radiotherapy, or concurrent hormonal therapy, was permitted, depending on each @entity1 's status. All the endpoints were evaluated under the principle of intention to treat analysis. RESULTS: A total of 24 @entity1 entered the study, and 18 had at least one measurable lesion, but 6 did not. The objective response rate of the 18 @entity1 was 50%(9/18). Two were complete responses and seven showed partial responses. The median response duration, progression free and overall survival were 5.3 months (range, 4~18), 6 months (95% CI, 5~7) and 12 months (95% CI, 7~17), respectively. 67% of the planned dose was administered. Out of a total 135 cycles administered, about 20% of cycles showed grade 3 or 4 @entity1431 and 7% showed grade 3 @entity882 . Two @entity1 suffered from @entity55 , and one experienced @entity221 . @entity33 , greater than grade 3, existed in three cases. No treatment related @entity204 were reported. CONCLUSION: The combination chemotherapy, with @entity1311 and @entity900 , was active in the treatment of metastatic @entity0 @entity1 having failed previous chemotherapy.

@entity1311 and XXXX Combination Chemotherapy in Pretreated @entity0 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity33 :: ('MESH:D052016', 'Disease') :: ['Mucositis'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
